Prothena Corporation plc
PRTAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Prothena Corporation plc focuses on Biotechnology services and products. Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. The company carries a $421.0M market cap, placing it firmly in the small-cap category. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Market Cap
$421.0M
Beta
-0.29
P/E (TTM)
—
P/E (Fwd)
-6.24
EPS (TTM)
$-0.82
EPS (Fwd)
$-1.31
ROE
-14.4%
ROA
-10.7%
Cash
$288.2M
Total Debt
$7.0M
Free CF
-$54.2M
52W Change
-20.9%
Annual Financials
Cash vs Debt
Where PRTA stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, PRTA finished 9.55% below its 150-day moving average ($9.32) and 9.26% below its 200-day moving average ($9.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRTA overbought or oversold?
At the October 13, 2026 close, PRTA's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Prothena Corporation plc holds $288.2M in cash against $7.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$54.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -14.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $53.9M to $9.7M.
PRTA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PRTA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.